Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

Wondering how to start your classic jewellery collection? Don’t worry we have got you covered. In an interview with experts, ...

Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT) are two of the biggest rivals in tech. And today, they're both spending heavily on artificial intelligence (AI) as their rivalry evolves into yet ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

Solitaire card games are addictive. Maybe that's why Microsoft solitaire games were so popular back in the day. Would you like to move those games to your Android device and play Spider or Klondike ...

(Bloomberg) -- Microsoft Corp. plans to spend $80 billion this fiscal year building out data centers, underscoring the intense capital requirements of artificial intelligence. More than half of ...

Mohan Kumar, an expert in Hyper-Scalable Temporal Data, drives innovation at AtoB; formerly of LinkedIn, Zenefits and D.E. Shaw. Startups and growing companies often face the pivotal question ...

Local police in Chile found three watches from “John Wick” actor Keanu Reeves’ luxury watch collection believed to have been stolen during a break-in at his Los Angeles home in late 2023 ...

Hedge fund billionaires Stephen Mandel and Louis Bacon sold shares of Microsoft and bought shares of Meta Platforms in the third quarter. Microsoft's artificial intelligence business is on pace to ...

Microsoft MSFT1.05%increase; green up pointing triangle is trying a new approach to build excitement for its artificial-intelligence assistant Copilot: Give it to customers whether they want it or ...

Mirum Pharmaceuticals has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential ...